The long-term effectiveness of pulmonary arterial hypertension-specific drug therapy (PAH-SDT) in Eisenmenger syndrome is controversial. We investigated short-term and long-term hemodynamic changes under PAH-SDT and their associations with outcomes in a bicentric cohort. METHODS: Over 20 years, we included 69 patients with congenital heart disease, an indexed pulmonary vascular resistance (PVRi) 48 WU Á m 2 , and 292 standardized catheterizations at baseline and after PAH-SDT initiation or intensification. Oxygen consumption was measured and the Fick principle applied to calculate indexed pulmonary output (Qpi) and PVRi. RESULTS: After PAH-SDT initiation or intensification, median (interquartile range) PVRi decrease was 5.1 WU Á m 2 (À1.4, À12.6) (p o 0.0001). Median Qpi and 6-minute walk test increases were þ0.4 liter/min/m
desaturation. 1 ES develops in 3.5% to 12.0% of adults with congenital heart disease. 2 PAH-specific drug therapies (PAH-SDTs) are designed to induce vasodilation of the pulmonary microvascular tree. Beneficial effects of PAHSDTs on functional class (FC) have been reported in patients with ES. 3, 4 PAH-SDT with bosentan is approved in Europe for patients with a World Health Organization FC (WHO-FC) of III or IV. 5 Evidence supporting the use of other PAH-SDTs in ES is less substantial. 5 More specifically, long-term effects and associations with mortality are unclear. 4, [6] [7] [8] [9] The objective of this large prospective cohort study in patients with ES was to assess short-term and longterm changes in multiple invasive hemodynamic parameters under PAH-SDT as well as their associations with outcomes including exercise capacity and clinical events.
Methods
We performed a bicentric observational cohort study in consecutive patients with congenital heart disease and an indexed pulmonary vascular resistance (PVRi) 48 Wood units (WU)/m 2 indicating either ES or non-correctable prevalent systemic-topulmonary shunt according to the NICE classification. 5, 10 Exclusion criteria were PAH with a closed defect, coincidental small cardiac defect, or patent foramen ovale. The 2 participating centers were referral centers for PAH and used the same standard-of-care protocol. Each included patient had at least 1 standardized right heart catheterization (RHC). All RHCs were done at the same laboratory. Data were collected prospectively in incident patients starting in 1994 by a single investigator (A.C.). The study database was reported to the French data protection authority (CNIL No. 1154338, April 27, 2006) . The study was approved by our institutional review board (No. CCML 2015-4). Written informed consent was obtained from each patient.
WHO-FC and the 6-minute walk test (6 0 WT) were assessed during the index hospitalization using a standardized method. 11 Blood was collected during RHC for hemoglobin concentration and hematocrit determination using multi-modality techniques (ABX Pentra DX 120; HORIBA Medical, Kyoto, Japan). Followup information was obtained by telephone calls to patients, relatives, or general practitioners.
RHCs were performed in hemodynamically stable and spontaneously breathing patients, under local anesthesia, without oxygen support. The supplementary text (available in the online version of this article at www.jhltonline.org) describes the catheterization method. Briefly, pressures were measured in cardiac chambers and vessels and averaged over several respiratory cycles. 12 Left atrial pressure was measured directly if there was a pre-tricuspid defect and estimated from the pulmonary wedge pressure otherwise. Oxygen consumption (VO 2 ) was measured using an indirect calorimeter that collected expired gas in a canopy hood (Deltatrac II; Datex, Helsinki, Finland, 1994-2012; Quark RMR; COSMED, Rome, Italy, thereafter). 13 Blood samples for staged oxygen saturation measurements were obtained (ABL80 FLEX CO-OX; Radiometer, Copenhagen, Denmark). Pulmonary output (Qp) was calculated using the Fick principle and then indexed (Qpi) to body surface area (Boyd formula). 14 The following hemodynamic data were collected: right atrial pressure; superior vena cava (SVC) oxygen saturation; pulsed peripheral arterial oxygen saturation; mean, diastolic, and systolic pulmonary artery pressures; pulmonary artery oxygen saturation; mean and systolic aortic pressures; pulmonary wedge pressure; left atrial pressure; VO 2 , and transpulmonary pressure gradient (TPG). PVRi was calculated as the ratio of TPG/Qpi. We defined a treatment step as initiation or intensification of PAH-SDT (initiation of PAH-SDT with 1 or 2 drugs or addition of a drug in a patient already taking 1 or 2 drugs). Changes between 2 time points in TPG, PVR, PVRi, Qpi, indexed pulmonary power input, and 6 0 WT were calculated after each treatment step as the difference (Δ) in median (interquartile range) values. PVR, PVRi, Qpi, and 6 0 WT were compared before and after each step using the Wilcoxon signed rank test. Changes after each step were evaluated after a few months and again at last follow-up examination before the next step. Spearman's coefficients were computed to assess correlations between changes in 6 0 WT and in hemodynamic parameters after each step.
Statistical methods
Assumptions were made to estimate the significance threshold for hemodynamic data changes and to take into account variability resulting from the measurement methods before the assessment of pressure-flow relationships (see supplementary text, available in the online version of this article at www.jhltonline. org). ΔQpi, ΔTPG, and ΔPVRi values below the threshold were considered non-significant and replaced by zero. Changes in corrected TPG were displayed according to corrected Qp on a polar diagram (Figure 1) . 15 We distinguished 3 patterns of hemodynamic change over time: improvement, defined as a significant Qpi increase and/or a significant TPG decrease; deterioration, defined as a significant Qpi decrease and/or a significant TPG increase; and stability, defined as no significant change in Qpi or TPG.
We used a composite criterion including 4 clinical events: death, heart-lung transplantation, lung transplantation, and listing for transplantation. Selection for listing was based on an assessment of each individual patient during a multi-disciplinary discussion that focused on FC and right heart failure parameters, without considering pulmonary pressures or PVR obtained during RHC. 16 Kaplan-Meier cumulative events curves were plotted using years since first RHC as the time scale. Differences in cumulative events curves according to hemodynamic data were assessed using the log-rank test.
Associations between baseline variables and outcome were assessed using a Cox proportional hazards model. Proportionality of hazards was evaluated by applying a test for correlation between the scaled Schoenfeld residuals and the logarithmic transformation of time. 17 Variables associated with p o 0.15 by univariate analysis were introduced into a multi-variate model and then subjected to stepwise backward selection. A significant interaction was observed between WHO-FC or 6 0 WT and the pattern of hemodynamic change; therefore, 6
0 WT and WHO-FC were excluded from the first model. A second model was built without the pattern of hemodynamic change but with WHO-FC and 6 0 WT. The interaction with WHO-FC tested by adding the interaction term to the model was not significant.
Results

Study population
We included 69 patients with 292 RHCs (median, 3 per patient; range, 1-14); 10 patients had a single RHC. Table 1 summarizes the demographic and hemodynamic data in the overall population and the 2 sub-groups defined by defect location. Atrial septal defects (ASDs) predominated (n ¼ 43 [62.3%], including 39 ostium secundum, 2 sinus venosus, and 2 ostium primum), followed by ventricular septal defects (n ¼ 13 [18.8%]), patent ductus arteriosus (n ¼ 6 [8.7%]), and aortopulmonary window (n ¼ 2 [2.9%]); the remaining 5 (7.2%) patients had combined defects (1 case each of patent ductus arteriosus and ASD, ostium secundum ASD and abnormal pulmonary venous return, and ventricular septal defect and patent ductus arteriosus and 2 cases of ventricular septal defect and ASD). RHC was followed by major adverse events in 2 cases (0.7%; 95% confidence interval [CI], 0.1%-2.5%). At the time of the first RHC, 54 (78.3%) patients were not taking PAH-SDT; 12 (17.4%) patients were taking a single PAH drug, and 3 (4.3%) were taking 2 PAH drugs. Of the 59 patients who had Z2 RHCs, at the last RHC, 3 (5.1%) were taking no PAH-SDT; 11 (18.6%) were taking a single PAH drug, 32 (54.3%) were taking 2 PAH drugs, and 13 (22.0%) were taking 3 PAH drugs. Figure 2 ), PVRi decreased significantly, and Qpi increased in the patients taking 1 or 2 PAH drugs but not in the small group (n ¼ 13) taking 3 PAH drugs. After a median follow-up of 4.9 years, no significant PVRi decrease or Qpi increase was observed compared with baseline, and only 37.4% of patients met our definition of hemodynamic improvement (increased Qpi and decreased TPG and PVRi). The patients taking 3 PAH drugs had a distinctive long-term profile with a persistent significant PVRi decrease. Table 3 shows the comparison of clinical and hemodynamic parameters in 50 patients stratified according to the hemodynamic pattern after the first treatment step with available RHC data. Distribution of treatment step types in these 50 patients was as follows: starting a first single drug, n ¼ 25; adding a second drug, n ¼ 11; adding a third drug, n ¼ 3; and starting PAH-SDT with 2 drugs simultaneously, n ¼ 11. A hemodynamic improvement occurred in 34 (68.0%; 95% CI, 53.3-80.5) patients, including the 6 patients with persistent left-to-right shunts ( Figure 1 ). Hemodynamic stability was more common in patients with post-tricuspid shunts. Patients with hemodynamic improvement (n ¼ 34 [68%]) or stability (n ¼ 8 [16%]) had worse baseline features with more dyspnea, higher PVRi, and lower Qpi compared with patients with hemodynamic deterioration. Patients with hemodynamic improvement had the largest PVRi decrease and largest Qpi increase so that their hemodynamic parameters at the second RHC were better than in the patients with hemodynamic stability or deterioration. Patients with hemodynamic deterioration had milder symptoms, lower PVRi, and higher Qpi despite similar pulmonary pressures at baseline. Decreases in both Qpi and TPG occurred in only 2 (4.0%) patients, who had compromised function and died during the follow-up period. This pattern was characterized by decreases in Qpi, systemic output, and TPG with no significant change in PVRi. Table 4 shows that the short-term and long-term changes in hemodynamic parameters were not significantly different in the sub-groups defined by defect location. Only the pattern of hemodynamic change was related to defect location in the short-term, with hemodynamic improvement being more common in the group with pre-tricuspid defects (p ¼ 0.008).
Functional parameters
An overall increase in 6
0 WT (þ44 m [þ6, þ80]) was observed. After each treatment step (Table 2), 6 0 WT 
From double to triple PAH-SDT (n ¼ 10) (Figure 3) . Median time to event was 8.1 years (range, 7.2 months to 13.6 years) after the first RHC and 2.6 years (range, 2 days to 8.8 years) after the last RHC. Age at events ranged from 18 to 62 years (median, 43.1 years (35.4-50.2)) with no significant difference according to defect location (p ¼ 0.75). The cumulative event rate 15 years after the first RHC was 49.2% ( Figure 4A ). Table 5 reports the results of the bivariate analysis comparing patients with and without events. Figure 4 shows the Kaplan-Meier curves of cumulative events according to clinical and hemodynamic parameters. Functional parameters at baseline were associated with events and all-cause mortality. Mortality was higher in patients with a shorter Changes in PVRi (A), TPG (B), Qpi (C), and 6 0 WT (D) after each PAH-SDT step.
Table 3 Clinical and Hemodynamic Parameters in 50 Patients Stratified According to Pattern of Hemodynamic Change After First PAH-SDT Step
Pattern of hemodynamic change, n ¼ 50 Continued on page 8
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Early patterns of hemodynamic change were significantly associated with events (p ¼ 0.008) and all-cause mortality (p ¼ 0.01). Events were more common in patients with stable or deterioration patterns compared with patients with the improvement pattern (HR, 3.8; 95% CI, 1.1-13.5; p ¼ 0.038) after adjustment for defect location, sex, PAH type (Nice classification), and number of anti-hypertensive drugs.
Discussion
In this large cohort of 69 patients with ES, we assessed hemodynamics using a standardized method over a 20-year period. This standardization is a major strength of our study, as it provides reliable data to evaluate the long-term effects of PAH-SDT. PAH-SDT initiation or intensification was associated with early hemodynamic improvements. Nevertheless, the hemodynamic effects of PAH-SDT varied across patients and declined over time. Hemodynamic parameter values at baseline and during PAH-SDT were associated with clinical events.
Methods used to investigate hemodynamics in ES
Some studies of PAH-SDT effects in ES failed to collect hemodynamic data. 8, 9 Echocardiography provides an assessment of right ventricular function but does not accurately investigate Qp and PVR. 18 In contemporary clinical practice, cardiac output measurement still relies on thermodilution or the Fick method, both of which are invasive. 19 In patients with congenital heart disease, thermodilution is inaccurate because the injected cold solution undergoes early recirculation or is lost through septal defects, and the Fick method is therefore the reference standard. VO 2 must be determined to compute cardiac output using the Fick method. 5, 20 Because direct VO 2 measurement is complex and requires sophisticated equipment, VO 2 is often estimated instead, not only in clinical practice but also in studies of ES. 3, 21, 22 However, the equations used to estimate VO 2 have been proven inaccurate in both adults and children. 20, 23, 24 Therefore, we measured VO 2 directly. 13 Furthermore, when assessing hemodynamic changes over time, we took the variability related to the measurement method into account.
Changes in hemodynamics and functional capacity induced by PAH-SDT
Overall, the short-term improvements in PVRi, Qpi, and functional capacity observed under PAH-SDT were consistent with improvements in previously reported placebocontrolled trials such as BREATHE-5. 3 However, the hemodynamic effects of PAH-SDT varied across patients. Thus, hemodynamics improved in only approximately 68% of patients.
PAH-SDT in idiopathic PAH is prescribed according to a stepwise strategy. 5 Few data are available on combination PAH-SDT in ES. Thus, the analysis of hemodynamic data in patients with ES given combination PAH-SDT is a strength Pattern of hemodynamic change, n ¼ 50 of our study. Combination therapy with bosentan and sildenafil failed to improve hemodynamic and functional parameters in a randomized, placebo-controlled, doubleblind trial in patients with ES. 25 However, sildenafil was added routinely after 3 months of treatment with bosentan. 25 In our cohort and in other studies of everyday clinical practice, stepwise treatment intensification with addition of a PAH drug when the previous treatment became inadequately effective was associated with a significant PVRi decrease and with significant increases in Qpi and 6 0 WT. 6 Furthermore, our data suggest that initiating PAH-SDT with 2 drugs in combination may provide greater hemodynamic improvements than a single initial drug.
In the long-term, after a median of nearly 5 years, the effects of PAH-SDT had lessened considerably, with only approximately 37% of patients still exhibiting the hemodynamic improvement pattern of Qpi increase and RVPi decrease. The 6 0 WT remained higher than at baseline, 6 but the size of the difference was similar to that reported previously during placebo therapy. 26 However, the study design did not allow us to determine whether the waning of PAH-SDT effects over time was related to PAH progression or to PAH-SDT escape phenomenon. In particular, we were unable to assess whether PAH-SDT slowed disease progression. In keeping with our data, a study of bosentan showed that the exercise parameters returned to baseline within 2 years. 7 The pattern of hemodynamic change was associated with the baseline data. The group with the hemodynamic improvement pattern had worse symptoms and higher PVRi at baseline compared with the other groups. In contrast, the hemodynamic deterioration pattern was associated with milder baseline symptoms and lower PVRi values compared with the other groups. PAH-SDT is recommended in patients with idiopathic PAH whose WHO-FC is II, III, or IV. 5 In ES, the effectiveness of PAH-SDT may be greatest in the WHO-FC III and IV classes. 5 Furthermore, differences in clinical phenotype and echocardiographic parameters exist between patients with pre-tricuspid and post-tricuspid defects. 27 In our cohort, post-tricuspid defects were associated with worse hemodynamic parameter values. 28, 29 Overall, hemodynamic changes induced by PAH-SDT were not significantly different between these 2 groups, in keeping with a sub-group analysis of data from BREATHE-5. 29 However, Figure 3 Distribution of events in the study population (N ¼ 69) . The data are numbers and percentages. in the patient-by-patient analysis, the hemodynamic improvement pattern was noted in only approximately 43% of the patients with post-tricuspid defects compared with approximately 78% of patients with pre-tricuspid defects. Thus, the response to PAH-SDT may differ according to defect location. 28 
Figure 4
Kaplan-Meier cumulative event curves in the overall population (A) and in sub-groups according to WHO status (B), pulmonary artery oxygen saturation (C), right atrial pressure (D), PVRi (E), aortic oxygen saturation (F), SVC oxygen saturation (G), and pattern of hemodynamic change under PAH-SDT (H).
Association between hemodynamics and outcome
Our study confirms the severity of ES, with approximately 37% of patients dying or requiring lung transplantation at a median age of 44.2 years. Similar severity was found in a large single-center study in which most patients had complex shunts. 8 Despite intensive PAH-SDT in our cohort, which included patients classified as WHO-FC II, the incidence of major events was high. The absence of a PAH-SDT-naïve group limits our ability to assess the impact of PAH-SDT on outcome. The above-mentioned retrospective single-center observational study 8 and a German registry study 9 suggested better survival with PAH-SDT, but neither study collected hemodynamic data. In our population, in addition to WHO-FC, several hemodynamic parameters predicted events, including PVRi, aortic oxygen saturation, 8, 27 right atrial pressure, pulmonary artery oxygen saturation, and SVC oxygen saturation. By multi-variate analysis, low SVC oxygen saturation was independently associated with events. In ES, low SVC oxygen saturation reflects both aortic oxygen desaturation and decreased systemic output. We also found that hemodynamic changes during PAH-SDT were strongly associated with events, whereas defect location was not. 27 However, immortal time bias may have occurred in the group with post-tricuspid defects. Our patients did not routinely undergo an accurate echocardiographic assessment of ventricular function, which strongly predicts outcome, 18 and therefore we were unable to determine whether invasive hemodynamic parameters provided additional predictive power.
Conclusions
In ES, the hemodynamic changes under PAH-SDT vary across patients and are associated with clinical events. The PAH-SDT strategy may need to be tailored to the hemodynamic changes.
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